louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06246409: Modernizing Instructions to Improve Treatment Participation of Subjects During Their First Radiotherapy
Official title: Modernizing Instructions to Improve Treatment Participation of Subjects During Their First Radiotherapy
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cancer
Keywords: patient comfort
patient participation
external beam radiotherapy
radiation oncology
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2024-02-07
Enrollment: 650
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: PREVENTION

Brief summary: Daily patient participation is critical to the successful, life-saving delivery of radiotherapy. There is very little in the literature describing the best way to prepare patients to give optimal participation. This study aims to look at an already-prepared conversion of patient instruction materials and measure whether the improvement in clarity and specificity produces the desired changes in patient decision-making and emotional comfort.


Eligibility criteria: Inclusion Criteria:

* Patients ≥ 18 years old planning their first external beam radiotherapy
* Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures.

Exclusion Criteria:

* Have received external beam radiotherapy in the past
* External beam radiotherapy is initiated as inpatient.
* External beam radiotherapy consists of less than 3 fractions.
* Planned radiotherapy that does not employ an external beam
* Planned participation in a clinical study that prohibits participation in a second, concurrent treatment trial
* Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.

Primary outcomes:
measure: Unintentional missed treatment days
timeFrame: 8 weeks
Secondary outcomes:
measure: Patient-reported comfort
timeFrame: 8 weeks
measure: Unplanned clinic visits
timeFrame: 8 weeks
measure: Emergency department visits
timeFrame: 8 weeks
measure: Hospitalizations
timeFrame: 8 weeks
measure: Rate of treatment completion
timeFrame: 8 weeks
measure: Patient participation in treatment
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Kathryn Hitchcock, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01007409: A Study to Assess Food Effect on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers
Official title: Randomized, Open-labeled, Single Dosing Study to Assess Food Effect on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: To assess food effect on the pharmacokinetics of fimasartan in healthy male volunteers
Lead sponsor: Boryung Pharmaceutical Co., Ltd
Sponsor class: INDUSTRY
First posted: 2009-11-04
Enrollment: 24
Sex: MALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: To assess food effect on the pharmacokinetics of fimasartan in healthy male volunteers.


Eligibility criteria: Inclusion Criteria:

* age: 20 - 45 years
* sex: male
* body weight: greater than 55 kg
* written informed consent

Exclusion Criteria:

* known allergy to Fimasartan
* existing cardiac or hematological diseases
* existing hepatic and renal diseases
* existing gastrointestinal diseases
* acute or chronic diseases which could affect drug absorption or metabolism history of any serious psychological disorder
* abnormal diet which could affect drug absorption or metabolism
* positive drug or alcohol screening
* smokers of 10 or more cigarettes per day
* participation in a clinical trial during the last 60 days prior to the start of the study

Primary outcomes:
measure: Cmax, Tmax, AUC, T1/2, CL/F etc.
timeFrame: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00590109: Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer
Official title: Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: Breast Cancer
Jewish
BRCA1
BRCA2
97-029
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
Collaborators: name: Sarah Lawrence College
name: University of Washington
First posted: 2008-01-10
Enrollment: 383
Sex: FEMALE
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A list of Jewish women diagnosed with breast cancer at Memorial Hospital after January 1994 will be generated from the hospital database. Patients that meet the study criteria will have a letter sent to their oncologist asking permission to invite the patient to participate in a study.

Brief summary: The purpose of this project is to further characterize inherited predisposition to breast cancer mediated by specific BRCA alleles (BRACA1 185delAG and 5382insC; BRCA2 6174delT) among Jewish women.


Eligibility criteria: Inclusion Criteria:

* Patients are eligible for the study if they are over 18 years of age, identify their ancestry as Jewish (both Sephardic and Ashkenazi Jews are eligible), have or have had a diagnosis of breast cancer, and are able to give informed consent.
* Relatives, age 18 or older, of the patients who meet eligibility criteria above and are found to have a specific BRCA1 or BRCA2 mutation if they are able to give informed consent.

Primary outcomes:
measure: to further characterize inherited predisposition to breast cancer mediated by specific BRCA alleles among Jewish women.
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Kenneth Offit, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05045209: Virtual Exercise Rehabilitation Treatment Program for Post Exacerbation of Chronic Obstructive Pulmonary Disease
Official title: Virtual Exercise Rehabilitation Treatment Program for Post Exacerbation of Chronic Obstructive Pulmonary Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COPD
Lead sponsor: St. Joseph's Healthcare Hamilton
Sponsor class: OTHER
Collaborators: name: Boehringer Ingelheim
First posted: 2021-09-16
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Admitted patients \>40years of age with documented diagnosis of COPD

Brief summary: Respiratory rehabilitation is an intervention proven to improve quality of life in those with chronic lung disease but access remains poor. The investigators will assess the feasibility and acceptability of a virtual platform for respiratory rehabilitation as an alternative to in person rehabilitation. The aim is to use the technology in those post admission with COPD where access has been even more of a challenge as during this period patients find it difficult to access an out patient program due to their frailty.

Detailed description: People living with lung disease struggle with activities. An exercise program can help but these programs are limited and are hard to get to and generally have a long wait list. The investigators will offer exercise and education through a tablet with internet provided 2 times per week for 10 weeks for patients admitted to hospital with a worsening of their COPD. Patients will work with a trained therapist for the exercise sessions and with the team for the education sessions. The investigators will assess outcomes on functional and quality of life improvements as well as feasibility and scalability of the technology.

Eligibility criteria: Inclusion Criteria:

* minimum age of 18 years
* maximum age of 90 years
* diagnosis of COPD

Exclusion Criteria:

* inability to perform exercise
* severe debilitating conditions

Primary outcomes:
measure: 6 minute walk test distance
timeFrame: 1 year
measure: 1-MSTST
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
measure: Daily activity levels
timeFrame: 1 year
Locations:
city: Hamilton
country: Canada
facility: St. Josephs' Hospital, Hamilton
state: Ontario
Study officials:
References:
Clinical trial NCT03425409: Aviation Portable Oxygen Delivery System
Official title: Aviation Portable Oxygen Delivery System Based on Pneumatic Pulse Technology
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Oxygen Delivery Systems at Altitude
Lead sponsor: Duke University
Sponsor class: OTHER
Collaborators: name: Odessey II Solutions
First posted: 2018-02-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: DEVICE_FEASIBILITY

Brief summary: This study aims to investigate dose based oxygen delivery vs. continuous flow of oxygen during simulated altitude conditions as would be experienced after a loss of pressure during commercial aircraft flight. Testing will be performed at rest and during light exercise at a simulated altitude of 15,000 feet in a hypobaric chamber. Performance of the two oxygen delivery systems will be compared using oxygen saturation determined by pulse oximetry.


Eligibility criteria: Inclusion Criteria:

* healthy volunteers

Exclusion Criteria:

* smoking
* pregnancy
* sickle cell trait
* cardiovascular or pulmonary disease
* significant ear or sinus problems that would prevent equalization during pressure change
* estimated VO2peak \<35 mL/kg per minute (males) or \<30 mL/kg per minute (females)

Primary outcomes:
measure: Device performance, as measured by SpO2
timeFrame: one minute
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Duke Universtiy Health System
name: Richard Moon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04244409: INvestigational Study Into Transplantation of the Uterus
Official title: INvestigational Study Into Transplantation of the Uterus
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Mayer-Rokitansky-Kuster Syndrome
Asherson's Syndrome
Postpartum Hemorrhage
Cervical Cancer
Keywords: Gynaecology
Immunosuppression
In-vitro Fertilisation
Infertility
MRKH
Pregnancy
Transplantation
Uterus
Lead sponsor: Womb Transplant UK
Sponsor class: OTHER
Collaborators: name: Oxford University Hospitals NHS Trust
name: Imperial College Healthcare NHS Trust
First posted: 2020-01-28
Enrollment: 10
Sex: FEMALE
Minimum age (years): 24
Maximum age (years): 38
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with absolute uterine factor infertility

Brief summary: Observational study on cohort of 10 women undergoing uterine transplantation using deceased donors


Eligibility criteria: Inclusion Criteria:

1. Female
2. Age - 24-38 (or 40 if eggs frozen \<38)
3. AUFI

   1. Normal length vagina
   2. No renal pathology
4. BMI \<30kg/m2
5. ASA grade I
6. Meet psychological criteria
7. Meet HFEA criteria for IVF
8. Eligible for NHS treatment
9. Speak fluent English

Exclusion Criteria:

1. Unsuccessful oocyte retrieval (\<10 good quality embryos)
2. Previous multiple/significant surgeries
3. Severe endometriosis
4. Cancer patients \<5 years in remission
5. Previous living childbirth, adopted child or child born through surrogacy
6. HIV or Hepatitis B / C positive
7. Skin or intestinal neovagina

Primary outcomes:
measure: Live birth rate
timeFrame: 5 years
Secondary outcomes:
measure: Pregnancy rate
timeFrame: 5 years
measure: Transplant success rate
timeFrame: 3 years
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Hammersmith Hospital, Imperial College NHS Trust
Study officials:
References:
Clinical trial NCT01389609: Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition
Official title: Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Study Assessing Bioequivalence Of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Hypertension
Keywords: Bioequivalence
Orally-disintegrating Tablet
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2011-07-08
Enrollment: 24
Sex: MALE
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: To test bioequivalence of Doxazosin 4 Mg Orally-disintegrating Tablet with Or Without Water to Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition


Eligibility criteria: Inclusion Criteria:

* Japanese healthy male subjects

Exclusion Criteria:

* Baseline orthostatic hypotension defined as a ≥20 mm Hg reduction in SBP, a ≥10 mm Hg reduction in DBP and/or the development of significant postural symptoms (dizziness, lightheadedness, vertigo) when going from the supine to standing position.

Primary outcomes:
measure: Peak plasma concentration (Cmax) and AUC from zero to the last sampling point (AUCt) of doxazosin 4 mg Orally Disintegrating Tablet (ODT) without water compared to doxazosin 4 mg Japanese marketed Immediate Release (IR) tablet under fasted conditions
timeFrame: up to 48 hours
Secondary outcomes:
measure: Cmax and AUCt of doxazosin 4 mg ODT with water compared to doxazosin 4 mg Japanese marketed IR tablet under fasted conditions.
timeFrame: up to 48 hours
measure: Other Pharmacokinetic (PK) parameters (Tmax, AUC from zero to infinity (AUCinf), AUC from zero to the last measurable point (AUClast), elimination rate constant (Kel), t½, and mean residence time (MRT) of doxazosin under all forms of
timeFrame: up to 48 hours
measure: administration.
timeFrame: up to 48 hours
Other outcomes:
Locations:
city: Shinjuku-ku
country: Japan
facility: Pfizer Investigational Site
state: Tokyo
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT02468609: Diagnostic Value of Ultralow-dose Computed Tomography for the Detection of Pulmonary Nodules and Lung Parenchym Alterations Compared to Standard-dose CT
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Multiple Pulmonary Nodules
Pulmonary Emphysema
Lead sponsor: Cantonal Hospital of St. Gallen
Sponsor class: OTHER
First posted: 2015-06-11
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To investigate the diagnostic value of ultralow-dose computed tomography in the detection of pulmonary nodules and lung parenchym alterations (e.g. emphysema) compared to standard-dose-CT.


Eligibility criteria: Inclusion Criteria:

* planned normal dose-CT by clinical indication at our institution
* obtained informed consent

Exclusion Criteria:

* planned lowdose-CT by clinical indication at institution
* no informed consent obtained
* age \< 18 years
* pregnancy

Primary outcomes:
measure: Number of pulmonary Nodules detected in the Ultralow-Dose thoracic CT
timeFrame: Participants CT-scan will be read out on an average date of 6 weeks after the scan
Secondary outcomes:
measure: Patients BMI (Body mass index)
timeFrame: Measures assessed at time of read-out on an average date of 6 weeks after the scan
measure: Patients Nodule size (mm)
timeFrame: Measures assessed at time of read-out on an average date of 6 weeks after the scan
Other outcomes:
Locations:
city: St. Gallen
country: Switzerland
facility: Klinik für Radiologie und Nuklearmedizin
Study officials:
References:
Clinical trial NCT02832609: Mechanisms of Orthopnea in Stable Obese Patients
Official title: Mechanisms of Orthopnea in Stable Obese Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: closing volume
expiratory flow limitation
obesity
orthopnea
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2016-07-14
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to study the role of closing volume as a determinant of orthopnea in stable obese subjects. The investigators hypothesized that: (1) increase in closing volume in supine position would be greater in orthopneic than in non-orthopneic subjects, and (2) the relationship of change in closing volume to change in dyspnea with position would be dependent on expiratory flow limitation in the sitting position.

In stable obese subjects, in sitting and supine positions, the investigators measured Borg dyspnea score, static lung volumes, expiratory flow limitation, and single-breath nitrogen expiration test, from which the investigators determined closing volume and closing capacity, slope of phase III, and opening capacity.

Orthopnea was defined as any increase in the Borg score in the supine position from its value in the sitting position


Eligibility criteria: Inclusion Criteria:

* obese (BMI ≥ 30)
* stable condition
* 20 \< Age \< 60 years

Exclusion Criteria:

* other respiratory disorder (COPD)
* left cardiac insufficiency

Primary outcomes:
measure: closing volume by nitrogen washout method
timeFrame: 30 minutes after changing position (hour 2)
Secondary outcomes:
measure: static lung volumes by plethysmography
timeFrame: 30 minutes after changing position (hour 2)
measure: expiratory flow limitation by NEP test
timeFrame: 30 minutes after changing position (hour 2)
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices civils de lyon, Hôpital de la Croix-Rousse - Réanimation, Surveillance Continue Médicales et Assistance Respiratoire
Study officials:
affiliation: Hospices Civils de Lyon
name: Claude Guérin, Prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Perino E, Nesme P, Germain M, Guerin C. Mechanisms of Orthopnea in Stable Obese Subjects. Respir Care. 2016 Aug;61(8):1015-22. doi: 10.4187/respcare.04146. Epub 2016 Apr 5.
Clinical trial NCT06553209: Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis
Official title: A Randomized, Double-blind, Single/Multiple Dose Escalation, Placebo-controlled Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM512 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Atopic Dermatitis
Lead sponsor: Keymed Biosciences Co.Ltd
Sponsor class: INDUSTRY
First posted: 2024-08-14
Enrollment: 94
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, double-blind, single/multiple dose escalation, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in healthy subjects and patients with moderate to severe atopic dermatitis.


Eligibility criteria: Inclusion Criteria:

* Have the ability to understand the study and voluntarily sign a written informed consent form (ICF).
* Body mass index (BMI) ranges from 18.0 to 26.0 kg/m2 (including boundary values).

Exclusion Criteria:

* Have participated in any clinical trials of drugs or medical devices within 3 months before the screening.
* Have severe infections, severe injuries, or undergone major surgical procedures within 3 months before screening.
* Have lost more than 400 mL of blood due to blood donation or other reasons within 3 months before screening.
* Positive drug abuse test or positive alcohol breath test result.

Primary outcomes:
measure: Adverse events
timeFrame: Up to 141 days or up to 169 days
Secondary outcomes:
Other outcomes:
Locations:
city: Chengdu
country: China
facility: West China Hospital of Sichuan University
state: Sichuan
Study officials:
affiliation: West China Hospital
name: Jingyi Li
role: PRINCIPAL_INVESTIGATOR
affiliation: West China Hospital
name: Ping Feng
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00001209: A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
Official title: A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Neuroectodermal Tumor, Primitive
Neuroepithelioma
Osteosarcoma
Sarcoma
Sarcoma, Ewing's
Keywords: Combined Chemotherapy
Irradiation
Unresectable
Lead sponsor: National Institutes of Health Clinical Center (CC)
Sponsor class: NIH
First posted: 2002-12-10
Enrollment: 120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: This protocol is designed to test the feasibility of the administration of vincristine, adriamycin and cytoxan, alternating with the newly developed regimen ifosfamide VP-16 as well as the efficacy of this therapy in addition to radiotherapy in producing complete responses and disease-free survival in patients with Ewing's sarcoma, primitive sarcoma of bone, peripheral neuroepithelioma, and soft tissue sarcoma. This will not be a randomized study but will be comparable to the large data base of similar patients treated on successive Pediatric Branch studies.

Detailed description: This protocol is designed to test the feasibility of the administration of vincristine, adriamycin and cytoxan, alternating with the newly developed regimen ifosfamide VP-16 as well as the efficacy of this therapy in addition to radiotherapy in producing complete responses and disease-free survival in patients with Ewing's sarcoma, primitive sarcoma of bone, peripheral neuroepithelioma, and soft tissue sarcoma. This will not be a randomized study but will be comparable to the large data base of similar patients treated on successive Pediatric Branch studies.

Eligibility criteria: Patients with high grade soft tissue sarcomas and either metastatic disease or stage III tumors including synovial sarcoma, malignant fibrous histiocytoma, hemangiopericytoma, malignant schwannoma (neurofibrosarcoma).

Patients must not have been previously treated with chemotherapy or radiation therapy.

The patients age must be less than or equal to 25 years.

The patient (or their guardian if under 18 years of age) must sign a document indicating that he/she is aware of the investigational nature of this treatment protocol and the potential risks and benefits that may be expected.

Patients must have a direct bilirubin of less than 4.0 mg/dl.

Patients must not have abnormal cardiac function (ejection fraction greater than 45% on MUGA scan with confirmation of shortening-fraction greater than 25% on echocardiography).

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bethesda
country: United States
facility: National Cancer Institute (NCI)
state: Maryland
Study officials:
References: